JP Morgan Cazenove Kept Victrex PLC (LON:VCT) As a “Neutral”; They Now Have a Target Price Of GBX 1800.00

Share

Victrex PLC (LON:VCT) Rating Reaffirmed

In a recent research report distributed to Clients on Wednesday, 9 December, The “Neutral” rating of Victrex PLC (LON:VCT) shares was has decided to restate by Analysts at JP Morgan Cazenove, who now has a GBX 1800.00 price target on the stock. JP Morgan Cazenove’s price target suggests a possible downside of -0.94% from the last stock close price of the company.

From a total of 16 analysts covering Victrex PLC (LON:VCT) stock, 8 rate it a ”Buy”, 1 a “Sell”, and 7 a ”Hold”. This means that 50% of the ratings are positive. The highest target price is GBX 2450 while the lowest target price is GBX 1700. The mean of all analyst targets is GBX 2133 with a 20.08% above today’s (GBX 1817) stock price. Victrex PLC was the topic of 26 analyst reports since July 22, 2015 according to the firm StockzIntelligence Inc. Deutsche Bank maintained shares on December 9 with “Hold” rating. UBS maintained shares with “Neutral” rating and GBX 2020 target share price in a report from an October 8. BNP Paribas maintained VCT stock in a recent report from December 1 with “Outperform” rating. N+1 Singer maintained the rating on October 8. N+1 Singer has a “Hold” rating and a GBX 2100 price target on shares. Finally, N+1 Singer maintained the stock with “Hold” rating in a report issued on a November 9.

Approximately 88,498 shares of stock traded hands. Victrex plc (LON:VCT) has declined 4.16% since May 12, 2015 and is downtrending. It has underperformed by 3.36% the S&P500.

JP Morgan Cazenove Kept Victrex PLC (LON:VCT) As a

Victrex plc is a United Kingdom-based firm engaged in the manufacture of polymer solutions. The company has a market cap of 1.56 billion GBP. The Company’s products are used in smartphones, gas and oil equipment, medical devices, aeroplanes and cars. It has 18.38 P/E ratio. The Firm has activities in industries such as Automotive, Aerospace, Electronics, Energy and Medical.

COMMENTS: